Date Filed | Type | Description |
08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/08/2023 |
8-K
| Quarterly results |
05/10/2023 |
SC 13G/A
| WELLINGTON MANAGEMENT GROUP LLP reports a 10.1% stake in Celldex Therapeutics, Inc. |
05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
05/04/2023 |
8-K
| Quarterly results |
04/25/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
04/25/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
03/21/2023 |
8-K
| Other Events Interactive Data |
02/28/2023 |
8-K
| Quarterly results |
02/14/2023 |
SC 13G/A
| VIKING GLOBAL INVESTORS LP reports a 0% stake in Celldex Therapeutics, Inc. |
02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/06/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
02/01/2023 |
SC 13G/A
| STATE STREET CORP reports a 4.9% stake in EXIT FILING CELLDEX THERAPEUTICS INC |
11/09/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
11/09/2022 |
8-K
| Quarterly results |
08/08/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
08/08/2022 |
8-K
| Quarterly results |
07/18/2022 |
8-K
| Quarterly results |
06/23/2022 |
8-K
| Quarterly results |
06/16/2022 |
8-K
| Quarterly results |
06/10/2022 |
SC 13G
| VIKING GLOBAL INVESTORS LP reports a 5.1% stake in Celldex Therapeutics, Inc. |
05/05/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
05/05/2022 |
8-K
| Quarterly results |
04/26/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
02/28/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
02/28/2022 |
8-K
| Quarterly results |
02/14/2022 |
SC 13G/A
| Redmile Group, LLC reports a 4.6% stake in Celldex therapeutics, Inc. |
02/14/2022 |
SC 13G/A
| RTW INVESTMENTS, LP reports a 8.4% stake in Celldex Therapeutics, Inc. |
02/10/2022 |
SC 13G
| STATE STREET CORP reports a 5.1% stake in INITIAL FILING CELLDEX THERAPEUTICS INC |
02/10/2022 |
SC 13G/A
| ADAGE CAPITAL PARTNERS GP, L.L.C. reports a 1.4% stake in Celldex Therapeutics, Inc. |
02/09/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
02/09/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/04/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
01/28/2022 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
|